Drug intelligence / Profile preview

XACT

Development stage: Unknown
Lead developer: Abbott
Modality: Small Molecules
Administration: Percutaneous, Implant

Overview

XACT is a branded pharmaceutical combination product manufactured by Zee Laboratories that contains chloramphenicol, beclomethasone, clotrimazole, and lignocaine. The product combines an antibacterial agent, a corticosteroid anti-inflammatory, an antifungal agent, and a local anesthetic, respectively, to address mixed inflammatory and infective conditions while also reducing pain and irritation. Based on this ingredient combination, XACT is most consistent with a topical otic or dermatologic preparation used for conditions in which bacterial and fungal overgrowth, inflammation, and local discomfort coexist.

Brand names: XACT

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)CYP (Cytochrome P450 family)Bacterial 50S ribosomal subunitGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on XACT.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XACT.

Explore the full profile